Q-omics provides the consensus-scored GRM5 profile across patient tissues and cancer cell-line models. GRM5 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GRM5 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, GRM5 RNA expression shows 13,546 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where GRM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRM5 survival associations across molecular data types. GRM5 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRM5 RNA expression–survival associations across cancer types. High GRM5 expression shows unfavorable associations in STAD and SCLC, but favorable associations in KIRC, HNSC, KIRP and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GRM5 RNA expression.
This table summarizes GRM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GRM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRM5 shows lower tumor expression in KICH and LUSC and higher tumor expression in BRCA, THCA, KIRP and KIRC. The KICH box plot shows higher GRM5 RNA expression in normal versus tumor tissue (log2 FC = −0.054, t-test p = .002).
This table shows molecular features associated with GRM5 in patient tissues and cancer cell lines. In patient samples, GRM5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
